[HTML][HTML] Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

…, B Glass, N Mounier, DS Gill… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell
transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (…

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised …

…, A Österborg, M Trneny, L Shepherd, DS Gill… - The lancet …, 2011 - thelancet.com
Background The MInT study was the first to show improved 3-year outcomes with the addition
of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like …

[HTML][HTML] Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the …

…, N Schmitz, N Mounier, DS Gill… - Journal of Clinical …, 2012 - ncbi.nlm.nih.gov
… Although all authors completed the disclosure declaration, the following author(s) and/or
an author's immediate family member(s) indicated a financial or other interest that is …

[PDF][PDF] Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem …

…, IW Prosser, KF Bradstock, L Coyle, DS Gill… - J Clin Oncol, 2009 - academia.edu
Purpose Thalidomide is effective in the treatment of newly diagnosed and relapsed/refractory
multiple myeloma (MM). However, the role of thalidomide in the post-autologous stem cell …

Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs)

AS Raw, MS Furness, DS Gill, RC Adams… - Advanced drug delivery …, 2004 - Elsevier
A sponsor of an Abbreviated New Drug Application (ANDA) must have information to show
that the proposed generic product and the innovator product are both pharmaceutically …

Pharmaceutical impurities: regulatory perspective for abbreviated new drug applications

…, AH Al Hakim, S Furness, NI Samaan, DS Gill… - Advanced drug delivery …, 2007 - Elsevier
Impurities in drug substances and drug products have been important regulatory issues in
the Office of Generic Drugs by having significant impact on the approvability of Abbreviated …

[HTML][HTML] Crop-ecology and nutritional variability influence growth and secondary metabolites of Stevia rebaudiana Bertoni

…, BS Gill, D Singh, G Chand, B Singh, RD Singh… - BMC Plant …, 2015 - Springer
Background Plant nutrition and climatic conditions play important roles on the growth and
secondary metabolites of stevia (Stevia rebaudiana Bertoni); however, the nutritional dose is …

Biopharmaceutical drug discovery using novel protein scaffolds

DS Gill, NK Damle - Current opinion in biotechnology, 2006 - Elsevier
In recent years, biopharmaceutical drug products have become hugely successful. However,
they are often complex molecules that are expensive to manufacture. Commercial needs …

[HTML][HTML] Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural …

…, MR Müller, CJ Barelle, W Somers, DS Gill… - Journal of Biological …, 2013 - ASBMB
The immunoglobulin new antigen receptors (IgNARs) are a class of Ig-like molecules of the
shark immune system that exist as heavy chain-only homodimers and bind antigens by their …

Laser operation of an Nd:Gd3Ga5O12 thin‐film optical waveguide fabricated by pulsed laser deposition

DS Gill, AA Anderson, RW Eason, TJ Warburton… - Applied physics …, 1996 - pubs.aip.org
We report the laser operation of a thin-film waveguide structure grown by the pulsed laser
deposition technique. A 2.7-m-thick crystalline film of neodymium doped Gd3Ga5O12 Nd: …